Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.

Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV.

J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11. Epub 2011 Oct 5.

2.

Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.

Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM.

J Clin Microbiol. 2011 Jan;49(1):269-74. doi: 10.1128/JCM.00914-10. Epub 2010 Oct 20.

3.

Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.

Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Crispell EK, Riahi F, McDanel JS, Satola SW, Doern GV.

Antimicrob Agents Chemother. 2014;58(2):740-5. doi: 10.1128/AAC.01915-13. Epub 2013 Nov 18.

4.

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Leonard SN, Rossi KL, Newton KL, Rybak MJ.

J Antimicrob Chemother. 2009 Mar;63(3):489-92. doi: 10.1093/jac/dkn520. Epub 2009 Jan 9.

PMID:
19136530
5.

Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.

Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.

BMC Infect Dis. 2013 Dec 10;13:583. doi: 10.1186/1471-2334-13-583.

6.

Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.

Sader HS, Jones RN, Rossi KL, Rybak MJ.

J Antimicrob Chemother. 2009 Nov;64(5):1024-8. doi: 10.1093/jac/dkp319. Epub 2009 Sep 10.

PMID:
19744978
7.

Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.

Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu TL, Wang JT.

J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31.

8.

Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.

Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R.

J Clin Microbiol. 2011 Jun;49(6):2147-50. doi: 10.1128/JCM.01435-10. Epub 2011 Apr 13.

9.

Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB.

J Clin Microbiol. 2011 Apr;49(4):1489-94. doi: 10.1128/JCM.02302-10. Epub 2011 Jan 26.

10.
11.

Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Satola SW, Farley MM, Anderson KF, Patel JB.

J Clin Microbiol. 2011 Jan;49(1):177-83. doi: 10.1128/JCM.01128-10. Epub 2010 Nov 3.

12.
13.

[The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].

Feng NN, Wang Q, Song YL, He LX, Zhou CM, Xie HM, Li HY.

Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):318-22. Chinese.

PMID:
23925360
14.

Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.

Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.

J Antimicrob Chemother. 2011 Jul;66(7):1594-9. doi: 10.1093/jac/dkr169. Epub 2011 Apr 26.

PMID:
21525024
15.

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV.

Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27.

16.

Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.

Sun W, Chen H, Liu Y, Zhao C, Nichols WW, Chen M, Zhang J, Ma Y, Wang H.

Antimicrob Agents Chemother. 2009 Sep;53(9):3642-9. doi: 10.1128/AAC.00206-09. Epub 2009 Jun 22.

17.

Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, Wootton M, Walsh TR.

J Clin Microbiol. 2008 Sep;46(9):3042-7. doi: 10.1128/JCM.00265-08. Epub 2008 Jul 2.

18.

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).

Sader HS, Becker HK, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Mar;66(3):329-31. doi: 10.1016/j.diagmicrobio.2009.09.017.

PMID:
20159377
19.

[Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].

Çıkman A, Aydın M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, Bayındır Bilmen F, Solmaz S, Özekinci T.

Mikrobiyol Bul. 2015 Apr;49(2):240-8. Turkish.

20.

Supplemental Content

Support Center